Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
This intro covers scenarios where a price-weighted index may be appropriate and how it contrasts with alternative indexing methods.
22,669 articlesA dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
In 2026, investors face a clash between disruption and durability: Archer Aviation as a high-growth upstart and Boein...
In the first half of 2026, Upstart stock fell about 19%, shaking confidence in a fintech darling. This article breaks...
Microsoft is doubling down on AI. This article lays out scenarios, risks, and concrete steps to understand where will...
A sharp weekly drain in Bitcoin ETF products highlights a split in investor demand. While BTC outflows led the pack, ...
ServiceNow has built a durable software platform with strong margins and steady growth. This article explains why the...
Cathie Wood’s big bet on CRISPR Therapeutics signals more than faith in gene editing. This article digs into the unde...
Powell's warning to Wall Street is shaping market expectations as AI optimism runs high. This article breaks down wha...
The AI revolution is just getting started, and a few names stand out as strong, long-term bets. This guide highlights...
As 2026 unfolds, investors face a choice between two very different travel giants. One leans on software and hosts to...
Dive into cadre holdings (cdre) 2025 with a clear, practical lens. This guide translates earnings chatter into real-w...
AVX's Q4 2025 results shed light on growth, profitability, and the path ahead. This article breaks down the numbers, ...